. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Eur J Nucl Med Mol Imaging. 2016 Dec 12;44(6):969–978. doi: 10.1007/s00259-016-3583-2

Table 5.

Multivariate Cox regression analysis using PET/CT parameters and Barcelona-Clinic Liver Cancer (BCLC) stage

Variable	Coefficient	P value	HR (95% CI)
BCLC B (vs. A/0)	0.20	0.870	1.22 (0.11-13.64)
BCLC C (vs. A/0)	1.07	0.300	2.92 (0.38-22.23)
BCLC D (vs. A/0)	1.63	0.284	5.09 (0.26-100.01)
SUV_max ≥ 11.7 (vs. < 11.7)	1.65	0.003^*	5.19 (1.73-15.56)
BCLC B (vs. A/0)	0.20	0.869	1.22 (0.11-13.65)
BCLC C (vs. A/0)	0.87	0.411	2.38 (0.30-18.84)
BCLC D (vs. A/0)	2.11	0.160	8.29 (0.44-157.75)
TLG ≥ 1341 (vs. < 1341)	0.97	0.033^*	2.64 (1.08-6.45)
BCLC B (vs. A/0)	0.05	0.968	1.05 (0.09-11.80)
BCLC C (vs. A/0)	0.83	0.436	2.29 (0.28-18.41)
BCLC D (vs. A/0)	2.17	0.150	8.73 (0.46-166.13)
MTV ≥ 230 mL (vs. < 230 mL)	0.89	0.053	2.44 (0.99-6.02)
BCLC B (vs. A/0)	0.22	0.861	1.24 (0.11-13.82)
BCLC C (vs. A/0)	1.16	0.260	3.19 (0.42-24.08)
BCLC D (vs. A/0)	1.69	0.273	5.43 (0.26-112.19)
TNR ≥ 4.8 (vs. < 4.8)	1.48	0.021^*	4.37 (1.24-15.38)

P < 0.05

CI, confidence interval; HR, hazard ratio; SUV_max, maximum standardized uptake value; TLG, total lesion glycolysis; MTV, maximum tumor volume; TNR, tumor-to-normal liver ratios of SUV.